InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,178.00
(
0.07%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
85.44
(
0.38%
)
Bitcoin
62,726.09
(
0.20%
)
Post# of 252444
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119956
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 138597

Tuesday, 03/13/2012 7:36:39 AM

Tuesday, March 13, 2012 7:36:39 AM

Post# of 252444

Does this mean PFE is out of Biosimilar on insulin now?

It would appear so. The main impediment to the PFE-Biocon insulin collaboration could have been the existence of Biocon’s broad FoB collaboration with MYL (#msg-72421544), which PFE may have perceived as a conflict of interest. Nevertheless, PFE is pushing ahead on its own with FoB’s for non-insulin drugs—e.g. #msg-72865371.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up